• Badar Ul Ahad Gill
  • Syed Naseem Iqbal Bukhari
  • Munir Ahmed Rashid
  • Muhammad Sohail Saleemi
  • Muhammad Zubair Zaffar


Background: Paroxysmal supraventricular tachycardia (PSVT) has always been a diagnostic and therapeutic challenge for the cardiologists. There are many modalities to treat the problem. Of the available pharmacological treatment, the role of verapamil and adenosine is under debate. This study was carried out to detect and compare the efficacy of both drugs. The objective of this study was to compare the efficacy of intravenous adenosine and verapamil in termination of PSVT. Methods: This experimental study was carried out in the Emergency department of Chauhdry Pervaiz Elahi Institute of Cardiology, Multan from to August 2008 to February 2010. A total of 120 patients with PSVT were divided in two groups. Patients in group A were treated with adenosine and group B patients received verapamil. Results: The efficacy of adenosine was proven among 56 (93%) patients, while verapamil in 43 (71%) patients. The results were statistically significant (p-value <0.05). Conclusions: Although, both the drugs have high efficacy, adenosine is more effective than verapamil for termination of PSVT.Keywords: Verapamil; adenosine; Paroxysmal supraventricular tachycardia


Denes P, Wu D, Dhingra RC, Chuquimia R, Rosen KM. Demonstration of dual AV nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation 1973;48:549–55.

Waldo AL, Wit AL. Mechanisms of cardiac arrhythmias. Lancet 1993;341:1189–93.

Jayam VKS, Calkins H. Supraventricular tachycardia, AV nodal re-entry and wolff-parkinsons-white syndrome. In: Valentin F, Wayne AR, O'Rourke, RA, Robert R, editors. Hurst’s The heart. 11th ed. USA: McGraw Hills; 2004.p. 855–73.

Ray IB. Narrow complex tachycardia: a recognition and management in the emergency room. J Assoc Physicians India 2004;52:816–24.

Steinbeck G, Reithmann C. Paroxysmal supraventricular tachycardia: preferential use of either adenosine or verapamil is dependant on the rate of tachycardia? Eur Heart J 2004;25:1277–8.

Ballo P, Bernabo D, Faraguti SA. Heart rate is a predictor of success in the treatment of adults with symptomatic paroxysmal supraventricular tachycardia. Eur Heart J 2004;25:1310–7.

Majeed I, Waheed I, Rauf A, Azhar M. Efficacy and adverse effects of adenosine in patients of supraventricular tachycardia. Ann King Edward Med Coll Uni 2004;10:353–5.

Atiq M. Therapeutic approach to paediatric PSVT. Pak Paeds Cardiol J 2000;2:18–22.

Rodriguez LM, de Chillou C, Schlapfer J, Metzger J, Baiyan X, van den Dool A, et al. Age at onset and gender of patients with different types of supraventricular tachycardias. Am J Cardiol 1992;70:1213–5.

Goyal R, Zivin A, Souza J, Shaikh SA, Harvey M, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J 1996;132:765–7.

Rosano GM, Leonardo F, Sarrel PM, Beale CM, De Luca F, Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347:786–8

Tada H, Oral H, Greenstein R, Pelosi F Jr, Knight BP, Strickberger SA, et al. Analysis of age of onset of accessory pathway-mediated tachycardia in men and women. Am J Cardiol 2002;89:470–1.

Delacrétaz E. Supraventricular Tachycardia. N Eng J Med 2006;354:1039–51.

Olgin JE, Zipes DP. Specific arrhythmia diagnosis and treatment. In: Libby P, Brown RO, Mann DL, et al. editors. Braunwald’s heart disease a text book of cardiovascular medicine. Philadelphia: Elsevier Saunders; 2005.p. 806–63.

Cairns CB, Neimann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991;20:717–21.

Lim SH, Anantharaman V, Teo WS, Chan Y. Slow infusion of calcium channel calcium channel blockers compared with intravenous adenosine in the emergency treatment of supraventricular tachycardia. Resuscitation 2009;80:523–8.

Ellenbogen KA , O’Neil G, Prystowsky EN, Camm JA, Meng L, Leiu HD, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during electrophysiological study with tecadenoson. Circulation 2005;111:3202–8.

Garrat C, Linker N, Griffith M, Ward D, Camm AJ. Comparison of Adenosine and Verapamil for termination of paroxysmal junctional Tachycardia. Am J Cardiol 1989;64:1310–6.

Rankin AC, Rae AP, Oldroyd KG, Cobbe SM. Verapamil or adenosine for the immediate treatment of supraventricular tachycardia. Q J Med 1990;274:203–8.

Hood MA, Smith WM. Adenosine versus Verapamil in the treatment of supraventricular tachycardia: a randomized control trial. Am Heart J 1992;123:1543–9.

Di Marco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med 1990;113:104–10.